Document Classification

Section Type: RESULTS

Text: Compared with placebo, conivaptan at 20 and 40 mg significantly reduced pulmonary capillary wedge pressure (-2. 6 + / -0. 7, -5. 4 + / -0. 7, and -4. 6 + / -0. 7 mm Hg for placebo and 20 and 40 mg groups, respectively ; P < 0. 05) and right atrial pressure (-2. 0 + / -0. 4, -3. 7 + / -0. 4, and -3. 5 + / -0. 4 mm Hg for placebo and 20 and 40 mg groups, respectively ; P < 0. 05) during the 3 - to 6-hour interval after intravenous administration.